Journals / Anadolu Kardiyoloji Dergisi / 2007 / Cilt: 7 - Sayı: 1

Pre-hospital thrombolytic therapy

Hastane öncesi trombolitik tedavi

Pages
59–64
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Until necessary policy and technical substructure are completed cardiology centers should apply the most suitable reperfusion strategy according with the guidelines, feasibilities and their experience.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Reperfusion therapy with intravenous thrombolytic agents in acute ST-segment elevation myocardial infarction reduces the infarct size, preserves ventricular function, and therefore reduces mortality.
📊
Key Findings & Data:Experimental and clinical studies also showed that time to successful reperfusion is a critical determinant of survival.
💡
Conclusion & Impact:Until necessary policy and technical substructure are completed cardiology centers should apply the most suitable reperfusion strategy according with the guidelines, feasibilities and their experience.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Reperfusion therapy with intravenous thrombolytic agents in acute ST-segment elevation myocardial infarction reduces the infarct size, preserves ventricular function, and therefore reduces mortality. Experimental and clinical studies also showed that time to successful reperfusion is a critical determinant of survival. In this paper the importance of very early (pre-hospital) thrombolysis, its comparison with percutaneous interventional therapy and the feasibility in Turkey are discussed. Although primary coronary interventions are preferred in patients with ST-segment elevation myocardial infarction intravenous, early bolus thrombolysis in the pre-hospital stage provides a therapeutic option as good as primary angioplasty. Until necessary policy and technical substructure are completed cardiology centers should apply the most suitable reperfusion strategy according with the guidelines, feasibilities and their experience.

Özet

Akut ST segment yüksekliği olan miyokard infarktüsünde intravenöz trombolitik ajanlarla reperfüzyon tedavisi infarkt alanını sınırlandırmakta, ventrikül fonksiyonlarını korumakta ve dolayısıyla mortaliteyi azaltmaktadır. Deneysel ve klinik çalışmalar başarılı reperfüzyon zamanını, hayatta kalmanın önemli bir belirteci olarak göstermiştir. Bu yazıda çok erken (hastane öncesi) trombolizin önemi, perkütan girişimsel tedavi ile karşılaştırması ve Türkiye’deki uygulanabilirliği tartışılmaktadır. ST segment yüksekliği olan akut miyokard infarktüs hastalarında primer koroner girişimler önerilmesine rağmen hastane öncesinde intravenöz erken bolus trombolitik tedavi primer anjiyoplasti kadar iyi bir tedavi seçeneği olmaktadır. Hastane öncesi trombolitik tedavi için gerekli yasal ve teknik alt yapı tamamlanana kadar kardiyoloji merkezleri tedavi rehberleri ile kendi imkan ve tecrübelerine dayanarak en uygun reperfüzyon stratejisini uygulamak sorumluluğunda olmalıdır.

🔖

Cite This Article

ZOGHİ, M. (2022). Pre-hospital thrombolytic therapy. Anadolu Kardiyoloji Dergisi, Cilt: 7 - Sayı: 1, 59–64. https://ajindex.com/articles/437222

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Tillet WS. Garner RL. The fibrinolytic activity of hemolytic streptococci. J Exptl Med 1933; 58: 485
  2. Braunwald E. Evolution of the management of acute myocardial infarction: a 20th century saga. Lancet 1998; 352: 1771-4
  3. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2: 349-60
  4. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB 3rd, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines; ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention. Circulation 2006; 113: 166-286
  5. Davies MJ. The pathophysiology of acute coronary syndromes. Heart. 2000; 83: 361-6
  6. Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardiovasc Res 1997; 33: 243-57
  7. Rezkalla SH, Kloner RA. Ischemic preconditioning and preinfarction angina in the clinical arena. Nat Clin Pract Cardiovasc Med 2004; 1: 96-102
  8. Schaper W, Binz K, Sass S, Winkler B. Influence of collateral blood flow and of variations in MVO2 on tissue-ATP content in ischemic and infarcted myocardium. J Mol Cell Cardiol 1987; 19: 19-37
  9. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wave front phenomenon of ischemic cell death
  10. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation 1977; 56: 786-94
  11. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994; 343: 311-22
  12. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. The International Study Group. Lancet 1990; 336: 71-5
  13. ISIS-3: a randomized comparison of streptokinase vs tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. Lancet 1992; 339: 753-70
  14. An international rand